Breaking News
Sort by:
Top Post
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]
Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel […]
Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published
Transcenta, a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing […]
Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
Tachyon Therapeutics, a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today […]
BRIM Biotechnology Announces First Patient Enrollment in Pivotal Phase 3 Clinical Trial of BRM421 for Dry Eye Disease
BRIM Biotechnology, a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure […]
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam […]
Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping & Ablation Catheter
Galvanize Therapeutics today announced the first human investigational use of its large-area, focal, Pulsed Electric […]
Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout
Atom Bioscience, a clinical-stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced […]
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
Maze Therapeutics, a company translating genetic insights into new precision medicines, has announced positive results […]
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Nektar Therapeutics today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of […]
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium
Forge Biologics, a genetic medicines development and manufacturing organization, announced today that Maria Escolar, M.D., […]
- Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Read more
- Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Read more
- BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Read more
- Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution Read more
- GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Read more